Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
CNTX Stock Chart & Stats
$1.44
$0.09(8.26%)
At close: 4:00 PM EST
$1.44
$0.09(8.26%)
Day’s Range― - ―
52-Week Range$0.49 - $2.59
Previous CloseN/A
Volume293.07K
Average Volume (3M)349.72K
Market Cap
$129.17M
Enterprise Value-$20.98M
Total Cash (Recent Filing)$83.52M
Total Debt (Recent Filing)$167.32K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 05, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding89,704,190
10 Day Avg. Volume640,711
30 Day Avg. Volume349,716
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.16K
Enterprise Value/Ebitda0.56
Forecast
1Y Price Target
$4.50Price Target Upside212.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentCTIM-76 shows promising antitumor activity in preclinical studies, potentially outperforming competitors with its high selectivity for CLDN6.
Financial StabilityThe company's strong balance sheet and solid healthcare investor base provide a stable financial foundation for future developments.
Strategic PositioningContext Therapeutics is advancing in the promising field of bispecific T cell engagers for solid tumors, a growing sub-category with strong industry interest.
Bears Say
Clinical MilestonesDelivery of initial dose-escalation data for CTIM-76 is anticipated only by mid-2026, which may delay investor excitement.
Market ChallengesCNTX shares face pressure due to challenging biotech markets and a perceived lack of immediate catalysts as portfolio development continues.
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.49 and its highest was $2.59 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $129.17M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 16 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.062 by -$0.028.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 89,704,190 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.062. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
Context Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (212.50% Upside)
$4.50 (212.50% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 681.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.35%
12-Months-Change
Fundamentals
Return on Equity
-37.25%
Trailing 12-Months
Asset Growth
-15.15%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$4.50
▲(212.50% Upside)
Technical Analysis
Adverum Biotechnologies
―
Whitehawk Therapeutics
―
Quince Therapeutics
―
Adagene
―
Anebulo Pharmaceuticals
―
Ownership Overview
1.38% Insiders
5.96% Mutual Funds
65.45% Other Institutional Investors
23.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---